196 related articles for article (PubMed ID: 24345005)
1. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Mazepa MA; Raval JS; Moll S; Ma A; Park YA
Br J Haematol; 2014 Mar; 164(6):900-2. PubMed ID: 24345005
[No Abstract] [Full Text] [Related]
2. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
Shortt J; Oh DH; Opat SS
N Engl J Med; 2013 Jan; 368(1):90-2. PubMed ID: 23281998
[No Abstract] [Full Text] [Related]
3. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
van Balen T; Schreuder MF; de Jong H; van de Kar NC
Eur J Haematol; 2014 Jan; 92(1):80-2. PubMed ID: 24118335
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
Yates S; Matevosyan K; Rutherford C; Shen YM; Sarode R
Transfusion; 2014 Aug; 54(8):2064-7. PubMed ID: 24655327
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
6. Antibody depletion by bortezomib through blocking of antigen presentation.
Park SJ; Cheong HI; Shin JI
N Engl J Med; 2013 Apr; 368(14):1364-5. PubMed ID: 23550684
[No Abstract] [Full Text] [Related]
7. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
8. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Treatment of refractory thrombotic thrombocytopenic purpura.
Ann Intern Med; 2003 Jan; 138(2):I38. PubMed ID: 12529111
[No Abstract] [Full Text] [Related]
10. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
[TBL] [Abstract][Full Text] [Related]
11. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease.
Lämmle B; Kremer Hovinga JA; George JN
Haematologica; 2008 Feb; 93(2):172-7. PubMed ID: 18245649
[No Abstract] [Full Text] [Related]
12. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
Cataland SR; Jin M; Lin S; Kraut EH; George JN; Wu HM
Am J Hematol; 2008 Dec; 83(12):911-5. PubMed ID: 18821711
[TBL] [Abstract][Full Text] [Related]
13. Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.
Stubbs MJ; Thomas M; Vendramin C; Sonesson E; Kjellman C; Järnum S; Stenberg Y; Elfving C; Scully M
Br J Haematol; 2019 Jul; 186(1):137-140. PubMed ID: 30488420
[No Abstract] [Full Text] [Related]
14. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
Zheng XL; Wu HM; Shang D; Falls E; Skipwith CG; Cataland SR; Bennett CL; Kwaan HC
Haematologica; 2010 Sep; 95(9):1555-62. PubMed ID: 20378566
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
Coppo P; Wolf M; Veyradier A; Bussel A; Malot S; Millot GA; Daubin C; Bordessoule D; Pène F; Mira JP; Heshmati F; Maury E; Guidet B; Boulanger E; Galicier L; Parquet N; Vernant JP; Rondeau E; Azoulay E; Schlemmer B;
Br J Haematol; 2006 Jan; 132(1):66-74. PubMed ID: 16371021
[TBL] [Abstract][Full Text] [Related]
16. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.
Grillberger R; Casina VC; Turecek PL; Zheng XL; Rottensteiner H; Scheiflinger F
Haematologica; 2014 Apr; 99(4):e58-60. PubMed ID: 24532042
[No Abstract] [Full Text] [Related]
17. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.
Ling HT; Field JJ; Blinder MA
Am J Hematol; 2009 Jul; 84(7):418-21. PubMed ID: 19507208
[TBL] [Abstract][Full Text] [Related]
18. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
[TBL] [Abstract][Full Text] [Related]
19. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.
Kosugi S; Matsumoto M; Ohtani Y; Take H; Ishizashi H; Fujimura Y; Kuyama J
Int J Hematol; 2005 Jun; 81(5):433-6. PubMed ID: 16158827
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.
Peyvandi F; Palla R; Lotta LA
Haematologica; 2010 Sep; 95(9):1444-7. PubMed ID: 20807984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
